GSA Capital Partners’s Niagen Bioscience NAGE Stock Holding History

GSA Capital Partners’s Portfolio NAGE Stock Details NAGE Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q2	–	Sell	-30,749	Closed	-$212K	–	2231
2025 Q1	$212K	Buy	+30,749	New	+$193K	0.02%	1376
2023 Q2	–	Sell	-103,742	Closed	-$159K	–	2019
2023 Q1	$159K	Buy	103,742 +23,874	+30%	+$42.5K	0.02%	1299
2022 Q4	$134K	Buy	+79,868	New	+$127K	0.02%	1274
2022 Q3	–	Sell	-19,176	Closed	-$32K	–	1932
2022 Q2	$32K	Sell	19,176 -35,113	-65%	-$68.7K	﹤0.01%	1307
2022 Q1	$134K	Buy	+54,289	New	+$148K	0.02%	1251
2021 Q2	–	Sell	-19,886	Closed	-$186K	–	1642
2021 Q1	$186K	Sell	19,886 -39,335	-66%	-$312K	0.03%	928
2020 Q4	$284K	Sell	59,221 -3,547	-6%	-$17.3K	0.05%	772
2020 Q3	$252K	Buy	+62,768	New	+$303K	0.04%	861
2018 Q4	–	Sell	-13,700	Closed	-$59K	–	1803
2018 Q3	$59K	Sell	13,700 -38,200	-74%	-$164K	﹤0.01%	1584
2018 Q2	$193K	Buy	+51,900	New	+$197K	0.01%	1542

Other funds holding NAGE

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return

TCM

Tieton Capital Management Yakima, Washington $299M AUM 54.55% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Arrowstreet Capital Boston, Massachusetts $185B AUM 39.58% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Nuveen Charlotte, North Carolina $369B AUM 31.66% 1-Year Est. Return

Connor, Clark & Lunn Investment Management (CC&L) Vancouver, British Columbia, Canada $43.4B AUM 51.29% 1-Year Est. Return

Qube Research & Technologies (QRT) London, United Kingdom $89.9B AUM 20.22% 1-Year Est. Return

GSA Capital Partners's NAGE Position: Q2 2025 in Review

GSA Capital Partners sold out of Niagen Bioscience (NAGE) in Q2 2025, closing a stake of 30,749 shares — an estimated $212K sold.

GSA Capital Partners first reported a position in NAGE in Q2 2018 and held it in 10 quarters. The position peaked at $284K in Q4 2020. 155 funds tracked by Wall St. Rank hold NAGE as of Q2 2025.

GSA Capital Partners reported no remaining Niagen Bioscience position as of Q2 2025 after selling out during the quarter.
GSA Capital Partners sold 30,749 Niagen Bioscience shares in Q2 2025, an estimated $212K.
GSA Capital Partners first reported a position in Niagen Bioscience in Q2 2018 and held it in 10 quarters.
GSA Capital Partners's Niagen Bioscience position peaked at $284K in Q4 2020.
155 funds tracked by Wall St. Rank held Niagen Bioscience as of Q2 2025.

Based on GSA Capital Partners's 13F filing for Q2 2025, filed 22 Jul 2025.